Virani Shafique
Insider CIK 1856081 · RXRX Chief Corp. Dev. Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2024-01-16 | 2024-01-18 | 18,000 | — | $0 | 361,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2024-01-16 | 2024-01-18 | 18,000 | $10.93 | $196.7K | 136,748 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2024-01-16 | 2024-01-18 | 18,000 | $2.22 | $40.0K | 154,748 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-12-15 | 2023-12-19 | 18,000 | — | $0 | 379,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-12-15 | 2023-12-19 | 18,000 | $2.22 | $40.0K | 154,748 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-12-15 | 2023-12-19 | 18,000 | $9.60 | $172.8K | 136,748 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-11-15 | 2023-11-17 | 18,000 | — | $0 | 397,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-11-15 | 2023-11-17 | 3,603 | $7.18 | $25.9K | 136,748 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-11-15 | 2023-11-17 | 18,000 | $6.51 | $117.2K | 140,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-11-15 | 2023-11-17 | 18,000 | $2.22 | $40.0K | 158,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-10-16 | 2023-10-18 | 18,000 | — | $0 | 415,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-10-16 | 2023-10-18 | 18,000 | $6.30 | $113.4K | 140,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-10-16 | 2023-10-18 | 18,000 | $2.22 | $40.0K | 158,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-09-15 | 2023-09-19 | 18,000 | — | $0 | 433,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-09-15 | 2023-09-19 | 18,000 | $8.66 | $155.9K | 140,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-09-15 | 2023-09-19 | 18,000 | $2.22 | $40.0K | 158,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-08-15 | 2023-08-17 | 18,000 | — | $0 | 451,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-08-15 | 2023-08-17 | 18,000 | $2.22 | $40.0K | 158,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-08-15 | 2023-08-17 | 18,000 | $9.25 | $166.5K | 140,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-08-15 | 2023-08-17 | 3,603 | $9.19 | $33.1K | 140,351 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-07-26 | 2023-07-27 | 20,000 | — | $0 | 469,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-26 | 2023-07-27 | 20,000 | $14.41 | $288.2K | 143,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-07-26 | 2023-07-27 | 20,000 | $2.22 | $44.4K | 163,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-07-25 | 2023-07-27 | 20,000 | — | $0 | 489,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-25 | 2023-07-27 | 20,000 | $14.30 | $286.0K | 143,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-07-25 | 2023-07-27 | 20,000 | $2.22 | $44.4K | 163,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-07-18 | 2023-07-19 | 30,000 | — | $0 | 509,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-07-18 | 2023-07-19 | 30,000 | $2.22 | $66.6K | 173,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-18 | 2023-07-19 | 30,000 | $13.74 | $412.2K | 143,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-07-17 | 2023-07-19 | 30,000 | — | $0 | 539,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-07-17 | 2023-07-19 | 30,000 | $2.22 | $66.6K | 173,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-07-17 | 2023-07-19 | 30,000 | $11.72 | $351.6K | 143,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-06-16 | 2023-06-20 | 30,000 | — | $0 | 569,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-06-16 | 2023-06-20 | 30,000 | $9.41 | $282.3K | 143,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-06-16 | 2023-06-20 | 30,000 | $2.22 | $66.6K | 173,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-06-15 | 2023-06-20 | 30,000 | — | $0 | 599,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-06-15 | 2023-06-20 | 30,000 | $2.22 | $66.6K | 173,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-06-15 | 2023-06-20 | 30,000 | $9.67 | $290.1K | 143,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-06-02 | 2023-06-05 | 17,865 | $8.93 | $159.5K | 143,954 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-06-01 | 2023-06-05 | 25,000 | $8.58 | $214.5K | 161,819 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-05-15 | 2023-05-17 | 2,230 | $5.60 | $12.5K | 185,102 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-02-16 | 2023-02-17 | 1,768 | $8.42 | $14.9K | 187,332 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-02-15 | 2023-02-17 | 7,486 | — | $0 | 629,469 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-02-15 | 2023-02-17 | 7,486 | $2.22 | $16.6K | 197,332 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-02-15 | 2023-02-17 | 7,486 | $8.33 | $62.4K | 189,846 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-02-15 | 2023-02-17 | 746 | $8.44 | $6.3K | 189,100 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2023-02-01 | 2023-02-03 | 212,507 | — | $0 | 212,507 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2023-02-01 | 2023-02-03 | 2,994 | $8.55 | $25.6K | 189,846 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2023-02-01 | 2023-02-03 | 10,837 | — | $0 | 192,840 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2023-02-01 | 2023-02-03 | 106,253 | — | $0 | 182,003 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2023-01-17 | 2023-01-19 | 5,000 | — | $0 | 636,955 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2023-01-17 | 2023-01-19 | 5,000 | $2.22 | $11.1K | 83,160 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2023-01-17 | 2023-01-19 | 10,000 | $9.16 | $91.6K | 73,160 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2022-12-15 | 2022-12-19 | 5,000 | — | $0 | 641,955 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2022-12-15 | 2022-12-19 | 5,000 | $2.22 | $11.1K | 88,160 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2022-12-15 | 2022-12-19 | 10,000 | $8.85 | $88.5K | 78,160 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2022-11-15 | 2022-11-17 | 5,000 | — | $0 | 646,955 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2022-11-15 | 2022-11-17 | 4,941 | $11.92 | $58.9K | 83,160 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2022-11-15 | 2022-11-17 | 5,059 | $12.70 | $64.2K | 88,101 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2022-11-15 | 2022-11-17 | 5,000 | $2.22 | $11.1K | 93,160 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-11-15 | 2022-11-17 | 613 | $11.86 | $7.3K | 88,160 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2022-10-14 | 2022-10-18 | 5,000 | — | $0 | 651,955 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2022-10-14 | 2022-10-18 | 5,000 | $10.63 | $53.2K | 88,773 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2022-10-14 | 2022-10-18 | 5,000 | $11.21 | $56.1K | 93,773 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2022-10-14 | 2022-10-18 | 5,000 | $2.22 | $11.1K | 98,773 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2022-09-15 | 2022-09-16 | 5,000 | — | $0 | 656,955 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2022-09-15 | 2022-09-16 | 5,000 | $2.22 | $11.1K | 103,773 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2022-09-15 | 2022-09-16 | 9,600 | $13.34 | $128.1K | 94,173 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2022-09-15 | 2022-09-16 | 400 | $13.97 | $5.6K | 93,773 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2022-08-16 | 2022-08-17 | 25,000 | — | $0 | 661,955 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | S Sale | 2022-08-16 | 2022-08-17 | 30,000 | $12.61 | $378.3K | 98,773 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2022-08-16 | 2022-08-17 | 25,000 | $2.22 | $55.5K | 128,773 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-08-15 | 2022-08-17 | 613 | $12.96 | $7.9K | 103,773 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-05-16 | 2022-05-18 | 870 | $5.67 | $4.9K | 104,386 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2022-02-04 | 2022-02-08 | 5,436 | — | $0 | 5,436 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award deriv | 2022-02-04 | 2022-02-08 | 80,450 | — | $0 | 80,450 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-02-04 | 2022-02-08 | 40,225 | — | $0 | 103,652 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | F Tax w/h | 2022-02-04 | 2022-02-08 | 1,114 | $11.40 | $12.7K | 105,256 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | A Award | 2022-02-04 | 2022-02-08 | 2,718 | — | $0 | 106,370 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise deriv | 2021-06-02 | 2021-06-04 | 45,045 | — | $0 | 686,955 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | M Exercise | 2021-06-02 | 2021-06-04 | 45,045 | $2.22 | $100.0K | 63,045 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 732,000 | — | $0 | 732,000 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | C Conversion deriv | 2021-04-20 | 2021-04-22 | 732,000 | — | $0 | 0 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 18,000 | — | $0 | 18,000 | SEC↗ |
| RXRX RECURSION PHARMACEUTICALS, | J Other | 2021-04-20 | 2021-04-22 | 18,000 | — | $0 | 0 | SEC↗ |